Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of ABT-126 in Mild-to-Moderate Alzheimer's Disease
2009-011424-64Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nelonicline in Alzheimer's disease (AD) (4 arms), sponsored by Abbott Laboratories. Primary endpoint: Primary efficacy - Alzheimer's Disease Assessment Scale. Started Aug 2009; status: completed.
02
Drugs
nelonicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-011424-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011424-64.